AstraZeneca wins over Teva on Pulmincort in DNJ

Bloomberg reports: The decision by U.S. District Court for the District of New Jersey to deny a request by Teva to throw out the case means the dispute will now go to trial, probably in January, London-based AstraZeneca said in a statement Sept. 24.

The ruling may postpone the introduction of cheaper copies of the Respules version of Pulmicort in the U.S. The brand brought in $1.45 billion for AstraZeneca last year, while U.S. sales of Respules gained 20 percent from 2006.